Products
- Solid Tumors
- Cardiovascular Diseases
- Hematological Malignancies
- Metabolic Diseases
- Neurological Diseases
- Pulmonary Diseases
- Diseased Tissue
- Circulating Nucelic Acids and Exosome Isolation
- Genomic DNA Isolation
- Cell Immortalization Products
- Immortalized Cell Lines
- Ready-to-Use Lentiviruses
- Reporter Cell Lines
Poster presented by CBI at CSHL Telomeres & Telomerase Meeting
ALT in a Panel of Human Cancer Cell Lines
Andrei Malykh, John Foulke, Fang Tian
Capital Biosciences, Inc., Rockville, MD; ATCC, Manassas, VA
Abstract: In this study, a total of 22 human cancer cell lines from the ATCC
repository were tested for ALT activity using C-circle assay. These cell
lines represent sarcoma and carcinoma derived from brain, bone, fat, skin,
muscle and fibrous tissue. In addition, cancer gene mutations of these 22
lines were analyzed in parallel with ALT activity. ALT was detected in
approximately 50% of osteosarcomas, soft tissue sarcomas, brain tumor and
other tested cell lines. ALT+ cell lines appeared to have relatively less
genetic mutations than ALT- cell lines.
About CBI
Capital Biosciences Inc. is a US-based manufacturer and supplier of high-quality research reagents and a provider of custom services for academic and governmental research institutes, and the pharmaceutical and biotechnology industries. The company is located in the I-270 Hi-Tech corridor in the state of Maryland, USA. For more information about CBI visit www.capitalbiosciences.com
About ATCC
ATCC is an independent, private, nonprofit biological resource center (BRC) and research organization.. For more information about ATCC please visit www.atcc.org